Ischaemic heart diseases, platelet function, diabetes mellitus Circulatory System
Conditions
Interventions
A total of 400 patients will be recruited for this study (100 for each group):
1. Control Cohort without diabetes
2. Control Cohort with diabetes
3. Patients with IHD and without diabetes
4. Patients
Sponsors
University of Reading
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Under investigation for stable ischaemic heart disease and scheduled for coronary angiography as part of clinical care
Exclusion criteria
Exclusion criteria: 1. Acute Coronary Syndrome in the past 12 months 2. P2Y12 inhibitors (including clopidogrel, tricagreolor and prasugrel) 3. Treatment dose anti-coagulation, including warfarin or novel anti-coagulant drugs (NOACS) 4. Other metabolic dysfunction 5. Evidence of alcohol or drug misuse 6. Unable to give informed consent 7. Aged <18 years 8. Pregnancy 9. Active or recent malignancy (<2 years) 10. Any underlying haematological pathologies 11. Renal disease (eGFR <30) 12. Liver Cirrhosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet function measured by aggregometry and flow cytometry at baseline and optionally at a second time point likely to be within 2 years of the angiogram appointment but may be up to 5 years after the start of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Levels of thrombus formation measured using confocal microscopy at baseline and optionally at a second time point likely to be within 2 years of the angiogram appointment but may be up to 5 years after the start of the study | — |
Countries
England, United Kingdom
Outcome results
None listed